Crit Care:脓毒症或感染性休克患者静脉维生素C治疗的效果分析

2023-03-15 MedSci原创 MedSci原创 发表于上海

在这项荟萃分析中,脓毒症或感染性休克患者的IVVC显著改善了delta SOFA评分,并缩短了血管加压药物使用的持续时间,然而它与短期死亡率的降低无关,并且不良事件风险较高。

脓毒症是一种危及生命的器官功能障碍,与宿主对感染的反应失调有关,脓毒症休克是一种死亡风险较高的脓毒症。这种疾病每年导致全球1100万人死亡,世界卫生组织将其视为一种初级健康威胁。尽管脓毒症在治疗方面取得了重大进展,但除了感染源控制、液体复苏和血管活性药物等基础治疗外,没有足够的证据支持其他治疗方法可提高死亡率,脓毒症幸存者往往会遭受残余器官损伤。因此,寻找有效、安全、经济的辅助治疗方法来降低脓毒症的死亡率和经济负担是非常必要的。

维生素C是一种强大的抗氧化药物,也是休克生存所需的许多生物合成酶的辅助因子,参与内源性抗利尿激素和去甲肾上腺素的合成。近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,该研究旨在更新随机对照试验(RCT)的荟萃分析,并进一步探讨脓毒症或感染性休克患者静脉注射维生素C (IVVC)的结果。

该研究是一项随机对照试验的荟萃分析,研究人员从PubMed、EMBASE和Clinical Trials.gov网站上检索了维生素C治疗脓毒症或感染性休克的随机对照试验(RCT),从数据库创建到2023年1月16日。该研究的主要结果是72-96小时的delta顺序器官衰竭评估(SOFA)评分。两名评审员根据资格标准独立评估RCT:(1)研究类型:RCT;(2)患者人群:≥18岁脓毒症或脓毒症休克患者;(3)干预:与标准治疗相比,任何剂量的IVVC作为单一治疗或与硫胺素或氢化可的松联合治疗,无干预或安慰剂(定义为对照组);(4) RCT描述短期死亡率或SOFA评分。然后,两位作者独立地从RCT中提取相关信息。

该荟萃分析共确定了18项RCT (n=3364例患者)。从基线到72-96小时,采用IVVC治疗delta SOFA评分(MD为-0.62;95%CI为-1.00至-0.25;p=0.001)和血管加压药物使用时间(MD为-15.07;95%CI为-21.59~-8.55;p<0.00001)有显著影响。IVVC治疗未显示可改善短期死亡率(OR为0.89;95%CI为0.77~1.04;p=0.14);然而,25-100 mg/kg/d剂量组与短期死亡率显著降低相关(OR为0.80;95%CI为0.65~0.97;p=0.03)。IVVC治疗不良事件增加(OR为1.98;95%CI为1.06~3.68;p=0.03)。

由此可见,在这项荟萃分析中,脓毒症或感染性休克患者的IVVC显著改善了delta SOFA评分,并缩短了血管加压药物使用的持续时间,然而它与短期死亡率的降低无关,并且不良事件风险较高。

原始出处:

Baofang Liang.et al.The outcome of IV vitamin C therapy in patients with sepsis or septic shock: a meta-analysis of randomized controlled trials.Critical Care.2023.https://ccforum.biomedcentral.com/articles/10.1186/s13054-023-04392-y

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-08-30 西西弗西西 来自辽宁省

    25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-04-04 ms7000001378082920 来自贵州省

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-20 ms2000001601509483 来自北京

    怎么看?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-17 123010d0m73暂无昵称 来自上海

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 ms9000001330963825 来自贵州省

    就评论一下 拿个分

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 ms8000000287906505 来自江苏省

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 ms8000000287906505 来自江苏省

    学了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 侠胆医心 来自上海

    https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 侠胆医心 来自上海

    #脓毒症##感染性休克#患者静脉#维生素C#治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2155270, encodeId=9f8521552e011, content=25-100 mg/kg/d剂量组与短期死亡率显著降低相关,最后总结是无关 相矛盾?, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=51ec5595586, createdName=西西弗西西, createdTime=Wed Aug 30 10:39:52 CST 2023, time=2023-08-30, status=1, ipAttribution=辽宁省), GetPortalCommentsPageByObjectIdResponse(id=2123595, encodeId=d20c212359527, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=defe6509396, createdName=ms7000001378082920, createdTime=Tue Apr 04 00:39:54 CST 2023, time=2023-04-04, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2120611, encodeId=bcf6212061157, content=怎么看?, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8568186587, createdName=ms2000001601509483, createdTime=Mon Mar 20 18:53:21 CST 2023, time=2023-03-20, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2120116, encodeId=c0882120116a0, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05a2375525, createdName=123010d0m73暂无昵称, createdTime=Fri Mar 17 10:02:23 CST 2023, time=2023-03-17, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119915, encodeId=63202119915cc, content=就评论一下 拿个分, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de2a6465235, createdName=ms9000001330963825, createdTime=Thu Mar 16 09:57:33 CST 2023, time=2023-03-16, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2119885, encodeId=512e2119885db, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:51:30 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119883, encodeId=af58211988363, content=学了, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1aa5476355, createdName=ms8000000287906505, createdTime=Thu Mar 16 08:49:20 CST 2023, time=2023-03-16, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2119881, encodeId=c4ff21198811a, content=https://www.medsci.cn/article/show_article.do?id=fbf3199815d2 有报道, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:47:02 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119880, encodeId=9059211988016, content=<a href='/topic/show?id=7a2f851921d' target=_blank style='color:#2F92EE;'>#脓毒症#</a>或<a href='/topic/show?id=2a575331391' target=_blank style='color:#2F92EE;'>#感染性休克#</a>患者静脉<a href='/topic/show?id=7b63e9065ee' target=_blank style='color:#2F92EE;'>#维生素C#</a>治疗的效果分析,这是很多医生喜欢的操作,此前有RCT证实没有明显的效果,未来希望逐步放弃这样的操作了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85192, encryptionId=7a2f851921d, topicName=脓毒症), TopicDto(id=53313, encryptionId=2a575331391, topicName=感染性休克), TopicDto(id=79065, encryptionId=7b63e9065ee, topicName=维生素C)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Thu Mar 16 08:46:03 CST 2023, time=2023-03-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2119864, encodeId=1b5821198646a, content=很好,, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a6722872067, createdName=12838646m75暂无昵称, createdTime=Thu Mar 16 08:09:30 CST 2023, time=2023-03-16, status=1, ipAttribution=湖南省)]
    2023-03-16 12838646m75暂无昵称 来自湖南省

    很好,

    0

相关资讯

JCI:中山大学黄曦团队发现SLAMF7调节多种微生物脓毒症期间巨噬细胞的炎症反应

该研究发现SLAMF7在脓毒症中的调控作用,揭示了SLAMF7与TRAF6/SHIP1在下游信号传递中的相互作用,可能为脓毒症治疗策略的制定提供支持。

脓毒症亚型:进一步认识理解脓毒症的一种框架

脓毒症被定义为感染引起失调的宿主反应所导致的致命性器官功能不全。它每年影响全世界大约5000万人,并且通常是致命的,即使及时应用循证指南也是如此。

脓毒症患者的液体复苏:最新见解

静脉液体(IV)复苏是脓毒症休克初期复苏的关键组成部分,国际共识指南建议至少给予30mL/kg等渗晶体液。其原理是恢复循环容量并优化每搏量。

NEJM:脓毒症所致低血压的早期限制性或自由输液效果比较

在脓毒症引起的低血压患者中,本试验中使用的限制性液体策略与自由液体策略相比,并没有导致90天出院前死亡率显著降低。

急诊科疑似脓毒症患者延迟使用抗生素的时间间隔与住院死亡率之间的关系

尽早使用抗生素是治疗脓毒症的基石,但抗生素最佳的给药时间仍然未知。本研究 对急诊科疑似脓毒症患者开始抗生素治疗的时间进行了定量分析,并评价延迟使用抗生素 的时间间隔与住院死亡率之间的关系。

Crit Care:中国住院脓毒症的发病率和死亡率

该研究的结果表明,脓毒症住院治疗的负担比以前估计的要大。地理差异表明在预防脓毒症方面需要更多的努力。